Washington University proposes to establish the Data Coordinating Center (DCC) for the Polycystic Kidney Disease Treatment Network (PKD-TN) within the Division of Biostatistics. WU performs a similar function for the NIDDK-sponsored CRISP study that is developing imaging parameters to follow the progression of Polycystic Kidney Disease (PKD). WU generally, and this investigative team specifically, has a strong record of experience as the DCC for multicenter studies. The DCC will participate as a key member of the Steering Committee, taking a leadership role in planning the studies, leading the statistical analyses and reporting of these studies. A web-based data entry system, based on the one currently being used for CRISP, will be customized for the needs of the PKD-TN. The DCC will serve as the communications hub for the PKD-TN, arranging meetings, telephone and electronic communications and producing and archiving study-related documents. A three-group, double-masked, randomized, multicenter, placebo-controlled trial will address whether either an ACE inhibitor or an angiotensenin 2 antangonist will retard the progression of renal impairment in PKD. The trial will enroll 1,800 PKD subjects with a wide range of renal function and follow them for 3-5 years. The primary endpoint will be that of time to death, ESRD or a doubling of the serum creatinine level. GFR levels will be assessed annually with a central laboratory and will be used as a secondary endpoint. The GFR measurements will allow us to address questions about variations in treatment effect according to the severity of renal impairment and the presence of common features of the disease such as hypertension and proteinuria. Blood and urine samples will be collected at baseline and annually and stored in the NIDDK's repository for future pharmocogenitic studies and future studies of biomarkers of the progression of PKD. An early Phase II trial of BMP-7, a cytokine which has an essential role in coordinating the formation of the emerging metanephos, is proposed. BMP-7 has been shown to maintain renal function in animal models with acute and chronic renal disease and to reduce renal hypertrophy. A simple, two-group, placebo controlled, randomized clinical trial will be conducted to determine whether BMP-7 can retard the growth rate of the kidneys in PKD subjects. MRI-based imaging will be used to measure kidney size for the trial.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01DK062401-01
Application #
6546504
Study Section
Special Emphasis Panel (ZDK1-GRB-3 (M1))
Program Officer
Meyers, Catherine M
Project Start
2002-08-15
Project End
2009-01-31
Budget Start
2002-08-15
Budget End
2003-01-31
Support Year
1
Fiscal Year
2002
Total Cost
$500,000
Indirect Cost
Name
Washington University
Department
Biostatistics & Other Math Sci
Type
Schools of Medicine
DUNS #
062761671
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Cornec-Le Gall, Emilie; Olson, Rory J; Besse, Whitney et al. (2018) Monoallelic Mutations to DNAJB11 Cause Atypical Autosomal-Dominant Polycystic Kidney Disease. Am J Hum Genet 102:832-844
Nowak, Kristen L; You, Zhiying; Gitomer, Berenice et al. (2018) Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol 29:571-578
Braun, William E; Abebe, Kaleab Z; Brosnahan, Godela et al. (2018) ADPKD Progression in Patients With No Apparent Family History and No Mutation Detected by Sanger Sequencing. Am J Kidney Dis 71:294-296
Cornec-Le Gall, Emilie; Chebib, Fouad T; Madsen, Charles D et al. (2018) The Value of Genetic Testing in Polycystic Kidney Diseases Illustrated by a Family With PKD2 and COL4A1 Mutations. Am J Kidney Dis 72:302-308
Dad, Taimur; Abebe, Kaleab Z; Bae, K Ty et al. (2018) Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease. Kidney Int Rep 3:619-624
Brosnahan, Godela M; Abebe, Kaleab Z; Rahbari-Oskoui, Frederic F et al. (2017) Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials. Curr Hypertens Rev 13:109-120
Torres, Vicente E; Abebe, Kaleab Z; Schrier, Robert W et al. (2017) Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease. Kidney Int 91:493-500
Irazabal, María V; Abebe, Kaleab Z; Bae, Kyongtae Ty et al. (2017) Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial. Nephrol Dial Transplant 32:1857-1865
Porath, Binu; Gainullin, Vladimir G; Cornec-Le Gall, Emilie et al. (2016) Mutations in GANAB, Encoding the Glucosidase II? Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease. Am J Hum Genet 98:1193-1207
Heyer, Christina M; Sundsbak, Jamie L; Abebe, Kaleab Z et al. (2016) Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol 27:2872-84

Showing the most recent 10 out of 19 publications